Drug Trial News

RSS

NEJM publishes results from Amgen's brodalumab Phase 2 trial on plaque psoriasis

Amgen announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine.

29 Mar 2012

Clovis commences CO-1686 Phase I/II study in NSCLC

Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.

29 Mar 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012

Out-of-hospital use of GIK as therapy for ACS patients needs to be assessed

Patients experiencing symptoms such as chest pain who received from paramedics an intravenous solution consisting of glucose-insulin-potassium (GIK) had no reduction in the rate of progression to heart attack and no improvement in 30-day survival, although GIK was associated with a lower rate of the composite outcome of cardiac arrest or in-hospital death, according to a study appearing in JAMA.

28 Mar 2012

Imatinib improves RFS, overall survival in GIST patients after surgery

Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead of 1 had improved recurrence-free survival and overall survival, according to a study in the March 28 issue of JAMA.

28 Mar 2012

Olaparib improves survival rates in platinum-sensitive relapsed serous ovarian cancer

Today at the Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women's Cancer®, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a "Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer."

28 Mar 2012

HAART does not completely suppress HIV in sexually active MSM

Researchers from Boston University School of Medicine (BUSM) and Fenway Health have found that highly active antiretroviral therapy (HAART) does not completely suppress HIV in the semen of sexually active HIV-infected men who have sex with men.

28 Mar 2012

First clinical trial to evaluate intravenous antibiotics for CF lung infection

Experts from Bristol and Nottingham are leading a major new national study to investigate whether intravenous antibiotics are effective in killing a common germ that causes dangerous complications in cystic fibrosis (CF) patients.

28 Mar 2012

GIK can reduce cardiac arrest or death in patients with acute coronary syndrome

Paramedics can reduce someone's chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium ("GIK") to people having a heart attack, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

28 Mar 2012

Lower dose of thrombolytics can treat moderate pulmonary embolism

Pulmonary embolism -- the sudden blockage of an artery in the lung -- is estimated to cause over 100,000 deaths each year in the U.S. Although thrombolytics, or "clot-buster" drugs, are currently reserved to treat only the most severe cases of pulmonary embolism, new data suggest that when used at lower doses, these drugs are also safe and effective for more common, moderate cases of pulmonary embolism, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

28 Mar 2012

Top-line results from two Targacept TC-6987 Phase 2 studies on asthma, type 2 diabetes

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.

28 Mar 2012

NY-ESO-1 vaccine shows promise against ovarian cancer, melanoma

An immunotherapy regimen incorporating poxviruses and targeting a particular tumor antigen, NY-ESO-1, has shown promise in treating two types of cancers.

27 Mar 2012

Rivaroxaban safer, effective than standard therapy in treating PE

A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism - a blockage of lung blood vessels usually caused by a clot - and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

SAR236553/REGN727 antibody reduces LDL by up to 72% in patients

A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering drugs such as statins or to the current standard of care, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Researchers launch major aspirin trial to eradicate H. pylori

Researchers have launched a major clinical trial to investigate whether eliminating a common stomach bug could help to make taking aspirin safer in some patients.

27 Mar 2012

Bolus intracoronary abciximab reduces infarct size in high-risk patients with STEMI

Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.

27 Mar 2012

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

26 Mar 2012

Theracurmin shows positive impact on human diastolic functions

The research group led by Dr. Koji Hasegawa, Director of the Translational Research Division at the National Hospital Organization Kyoto Medical Center and Dr. Tatsuya Morimoto, Professor at the Molecular Medicine School of Pharmaceutical Sciences, University of Shizuoka, announced today based on the recent human clinical trials, that Theracurmin has continuously shown positive impact on human diastolic functions.

26 Mar 2012

Promising results from Esperion ETC-1002 Phase 2 clinical trial for dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced positive results from a Phase 2 clinical trial for ETC-1002.

26 Mar 2012

Results from Merck's vorapaxar study on cardiovascular events

Researchers today presented and published results from the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar, Merck's investigational anti-thrombotic medicine, in patients with a prior history of cardiovascular events or disease.

26 Mar 2012